Table 3:

Investigator-assessed objective response rate and disease control rate in biomarker-defined patient populations

Patients, n (%)	dMMR/MSI-H per local assessment (N=74)
	Objective response rate	Disease control for ≥12 weeks
Tumour PD-L1 expression
≥1% (n=21)	6 (28·6)	11 (52·4)
<1% (n=47)	13 (27·7)	35 (74·5)
Immune cell PD-L1 expression
Rare (n=24)	5 (20·8)	14 (58·3)
Intermediate (n=21)	5 (23·8)	17 (81·0)
Numerous (n=23)	9 (39·1)	15 (65·2)
Mutation status
BRAF mutant (n=12)	3 (25·0)	9 (75·0)
KRAS mutant (n=26)	7 (26·9)	16 (61·5)
BRAF/KRAS wild type (n=29)	12 (41·4)	23 (79.3)
Clinical history of Lynch syndrome*
Yes (n=27)	9 (33·3)	19 (70·4)
No (n=28)	8 (28·6)	21 (75·0)

dMMR/MSI-H=DNA mismatch repair deficient/microsatellite instability–high; PD-L1=programmed death-1 ligand 1.

^*Lynch syndrome designation was based on the clinical records of the patients at sites in countries where this reporting was permitted (excluded Italy).